Details of the Drug

General Information of Drug (ID: DMPIHLS)

Drug Name

Diclofenac

Synonyms

Diclofenac (sodium matrix patch, pain)

Indication

Disease Entry	ICD 11	Status	REF
Chronic renal failure	GB61.Z	Approved	[1]
Dysmenorrhea	GA34.3	Approved	[1]
Knee osteoarthritis	FA01	Approved	[1]
Osteoarthritis	FA00-FA05	Approved	[2]
Pain	MG30-MG3Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Neurology Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

296.1

Logarithm of the Partition Coefficient (xlogp)

4.4

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 10-40 min [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The clearance of drug is 16 L/h [5]
Elimination: 60-70% of the total dose is eliminated in the urine and 30% is eliminated in the feces [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2 hours [6]
Metabolism: The drug is metabolized via the CYP2C9 []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 10.85321 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.005% [6]
Vd: The volume of distribution (Vd) of drug is 5-10 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.14 mg/mL [4]

Chemical Identifiers

Formula: C14H11Cl2NO2
IUPAC Name: 2-[2-(2,6-dichloroanilino)phenyl]acetic acid
Canonical SMILES: C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
InChI: InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
InChIKey: DCOPUUMXTXDBNB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3033
ChEBI ID: CHEBI:47381
CAS Number: 15307-86-5
DrugBank ID: DB00586
TTD ID: D0TG1H
VARIDT ID: DR00681
INTEDE ID: DR0488
ACDINA ID: D00192

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Modulator	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[12]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[13]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[13]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[14]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[15]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[16]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[17]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Substrate	[18]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[18]
Cholesterol 24-hydroxylase (CYP46A1)	DEKP5HX	CP46A_HUMAN	Substrate	[19]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[20]
Cytochrome P450 105D7 (cyp105)	DECV2ME	CYP28_STRAW	Substrate	[21], [22]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLCG1)	OTSBQR6D	PLCG1_HUMAN	Gene/Protein Processing	[23]
14-3-3 protein beta/alpha	OTGBS3RF	1433B_HUMAN	Gene/Protein Processing	[23]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[24]
14-3-3 protein theta	OTWG7F3H	1433T_HUMAN	Gene/Protein Processing	[23]
15-hydroxyprostaglandin dehydrogenase (HPGD)	OTYZI6JB	PGDH_HUMAN	Gene/Protein Processing	[25]
2'-5'-oligoadenylate synthase 1 (OAS1)	OT8ZLOCY	OAS1_HUMAN	Gene/Protein Processing	[26]
3-phosphoinositide-dependent protein kinase 1 (PDPK1)	OTT09ZVP	PDPK1_HUMAN	Gene/Protein Processing	[23]
5-aminolevulinate synthase, erythroid-specific, mitochondrial (ALAS2)	OTJXOUCL	HEM0_HUMAN	Gene/Protein Processing	[23]
Actin, alpha skeletal muscle (ACTA1)	OTOVGLPG	ACTS_HUMAN	Gene/Protein Processing	[23]
Activin receptor type-1 (ACVR1)	OT4JATFE	ACVR1_HUMAN	Gene/Protein Processing	[23]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Diclofenac

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Naproxen	DMZ5RGV	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Naproxen.	Osteoarthritis [FA00-FA05]	[27]
-----------

Coadministration of a Drug Treating the Disease Different from Diclofenac (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[28]
Repaglinide	DM5SXUV	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Repaglinide.	Acute diabete complication [5A2Y]	[29]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Glibenclamide.	Acute diabete complication [5A2Y]	[29]
Tolazamide	DMIHRNA	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Tolazamide.	Acute diabete complication [5A2Y]	[29]
Nateglinide	DMLK2QH	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Nateglinide.	Acute diabete complication [5A2Y]	[29]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Glipizide.	Acute diabete complication [5A2Y]	[29]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Diclofenac due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[30]
Oxandrolone	DMU9MYJ	Moderate	Decreased metabolism of Diclofenac caused by Oxandrolone mediated inhibition of CYP450 enzyme.	Alcoholic liver disease [DB94]	[28]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Inotersen.	Amyloidosis [5D00]	[30]
Nifedipine	DMSVOZT	Moderate	Antagonize the effect of Diclofenac when combined with Nifedipine.	Angina pectoris [BA40]	[31]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[32]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Diclofenac and Cilostazol.	Arterial occlusive disease [BD40]	[33]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Budesonide.	Asthma [CA23]	[34]
Ofloxacin	DM0VQN3	Moderate	Additive CNS depression effects by the combination of Diclofenac and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Kanamycin.	Bacterial infection [1A00-1C4Z]	[36]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS depression effects by the combination of Diclofenac and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Streptomycin.	Bacterial infection [1A00-1C4Z]	[36]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS depression effects by the combination of Diclofenac and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[35]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Diclofenac and ABT-492.	Bacterial infection [1A00-1C4Z]	[35]
Gentamicin	DMKINJO	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Gentamicin.	Bacterial infection [1A00-1C4Z]	[36]
Netilmicin	DMRD1QK	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Netilmicin.	Bacterial infection [1A00-1C4Z]	[36]
Levofloxacin	DMS60RB	Moderate	Additive CNS depression effects by the combination of Diclofenac and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Tobramycin	DMUI0CH	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Tobramycin.	Bacterial infection [1A00-1C4Z]	[36]
Lomefloxacin	DMVRH9C	Moderate	Additive CNS depression effects by the combination of Diclofenac and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[35]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Etidronic acid.	Bone paget disease [FB85]	[37]
Risedronate	DM5FLTY	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Risedronate.	Bone paget disease [FB85]	[37]
Alendronate	DMY2KX9	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Alendronate.	Bone paget disease [FB85]	[37]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Diclofenac and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[38]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Diclofenac caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Diclofenac caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[40]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Diclofenac and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[33]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Iodipamide.	Cholelithiasis [DC11]	[41]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Phenylbutazone.	Chronic pain [MG30]	[27]
Ketoprofen	DMRKXPT	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Ketoprofen.	Chronic pain [MG30]	[27]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Diclofenac and Levomilnacipran.	Chronic pain [MG30]	[42]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Diclofenac and Anisindione.	Coagulation defect [3B10]	[33]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Diclofenac and Regorafenib.	Colorectal cancer [2B91]	[30]
Methoxyflurane	DML0RAE	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Methoxyflurane.	Corneal disease [9A76-9A78]	[30]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Diclofenac and Ardeparin.	Coronary thrombosis [BA43]	[43]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Diclofenac caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[44]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Diclofenac caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[45]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Diclofenac caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[46]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Diclofenac and Danaparoid.	Deep vein thrombosis [BD71]	[43]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Diclofenac and Rivaroxaban.	Deep vein thrombosis [BD71]	[47]
Aprepitant	DM053KT	Moderate	Increased metabolism of Diclofenac caused by Aprepitant mediated induction of CYP450 enzyme.	Depression [6A70-6A7Z]	[48]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Diclofenac and Sertraline.	Depression [6A70-6A7Z]	[42]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Diclofenac and Vilazodone.	Depression [6A70-6A7Z]	[42]
Paroxetine	DM5PVQE	Moderate	Increased risk of bleeding by the combination of Diclofenac and Paroxetine.	Depression [6A70-6A7Z]	[42]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Diclofenac and Vortioxetine.	Depression [6A70-6A7Z]	[42]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Diclofenac and Escitalopram.	Depression [6A70-6A7Z]	[42]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Diclofenac and Desvenlafaxine.	Depression [6A70-6A7Z]	[42]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Diclofenac and Clomipramine.	Depression [6A70-6A7Z]	[42]
PMID28870136-Compound-49	DMTUC9E	Moderate	Increased risk of bleeding by the combination of Diclofenac and PMID28870136-Compound-49.	Discovery agent [N.A.]	[49]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Diclofenac caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[50]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Diclofenac caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Cannabidiol.	Epileptic encephalopathy [8A62]	[30]
Ethacrynic acid	DM60QMR	Moderate	Antagonize the effect of Diclofenac when combined with Ethacrynic acid.	Essential hypertension [BA00]	[51]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Mefenamic acid.	Female pelvic pain [GA34]	[27]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Diclofenac and Tazemetostat.	Follicular lymphoma [2A80]	[33]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Diclofenac caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[28]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Diclofenac and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[30]
Sulfinpyrazone	DMEV954	Moderate	Increased risk of bleeding by the combination of Diclofenac and Sulfinpyrazone.	Gout [FA25]	[33]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Diclofenac and Eplerenone.	Heart failure [BD10-BD1Z]	[52]
Chlorothiazide	DMLHESP	Moderate	Antagonize the effect of Diclofenac when combined with Chlorothiazide.	Heart failure [BD10-BD1Z]	[51]
Amiloride	DMRTSGP	Moderate	Antagonize the effect of Diclofenac when combined with Amiloride.	Heart failure [BD10-BD1Z]	[51]
Bumetanide	DMRV7H0	Moderate	Antagonize the effect of Diclofenac when combined with Bumetanide.	Heart failure [BD10-BD1Z]	[51]
Hydroflumethiazide	DMVPUQI	Moderate	Antagonize the effect of Diclofenac when combined with Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[51]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Diclofenac caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[28]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Diclofenac caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[53]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[54]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Diclofenac caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Diclofenac caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Diclofenac caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Gemfibrozil	DMD8Q3J	Moderate	Decreased metabolism of Diclofenac caused by Gemfibrozil mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[28]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Diclofenac caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[28]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Diclofenac and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[57]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Diclofenac and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[58]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Diclofenac and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[59]
Indapamide	DMGN1PW	Moderate	Antagonize the effect of Diclofenac when combined with Indapamide.	Hypertension [BA00-BA04]	[51]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Diclofenac when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[51]
Hydrochlorothiazide	DMUSZHD	Moderate	Antagonize the effect of Diclofenac when combined with Hydrochlorothiazide.	Hypertension [BA00-BA04]	[51]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Diclofenac and Dipyridamole.	Hypertension [BA00-BA04]	[33]
Potassium chloride	DMMTAJC	Moderate	Increased risk of hyperkalemia by the combination of Diclofenac and Potassium chloride.	Hypo-kalaemia [5C77]	[60]
Fludrocortisone	DMUDIR8	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Fludrocortisone.	Hypo-osmolality/hyponatraemia [5C72]	[34]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Balsalazide.	Indeterminate colitis [DD72]	[61]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[27]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Diclofenac and Porfimer Sodium.	Lung cancer [2C25]	[62]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Diclofenac caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[28]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Diclofenac and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[63]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Idelalisib.	Mature B-cell leukaemia [2A82]	[64]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Diclofenac and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[65]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Clofarabine.	Mature B-cell lymphoma [2A85]	[30]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Diclofenac and Ibrutinib.	Mature B-cell lymphoma [2A85]	[66]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Diclofenac and Ponatinib.	Mature B-cell lymphoma [2A85]	[67]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Diclofenac due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[28]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Diclofenac caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[30]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Exjade.	Mineral absorption/transport disorder [5C64]	[68]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Diclofenac and Panobinostat.	Multiple myeloma [2A83]	[28]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Deflazacort.	Muscular dystrophy [8C70]	[34]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Diclofenac caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[69]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Diclofenac and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[33]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Diclofenac caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[70]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Diclofenac and Dasatinib.	Myeloproliferative neoplasm [2A20]	[71]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Diclofenac and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[72]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Diclofenac and Prasugrel.	Myocardial infarction [BA41-BA43]	[30]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Diclofenac and Vorapaxar.	Myocardial infarction [BA41-BA43]	[73]
Tirofiban	DMQG17S	Moderate	Increased risk of bleeding by the combination of Diclofenac and Tirofiban.	Myocardial infarction [BA41-BA43]	[74]
Modafinil	DMYILBE	Minor	Increased metabolism of Diclofenac caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[75]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Diclofenac and Sibutramine.	Obesity [5B80-5B81]	[42]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Diclofenac and Dexfenfluramine.	Obesity [5B80-5B81]	[42]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Diclofenac when combined with Polythiazide.	Oedema [MG29]	[51]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Diclofenac and MK-4827.	Ovarian cancer [2C73]	[30]
Aspirin	DM672AH	Moderate	Increased risk of bleeding by the combination of Diclofenac and Aspirin.	Pain [MG30-MG3Z]	[33]
Etodolac	DM6WJO9	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Etodolac.	Pain [MG30-MG3Z]	[27]
Diflunisal	DM7EN8I	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Diflunisal.	Pain [MG30-MG3Z]	[27]
Ibuprofen	DM8VCBE	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Ibuprofen.	Pain [MG30-MG3Z]	[27]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Diclofenac caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[76]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Diclofenac caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[77]
Prednisone	DM2HG4X	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Prednisone.	Postoperative inflammation [1A00-CA43]	[34]
Hydrocortisone	DMGEMB7	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Hydrocortisone.	Postoperative inflammation [1A00-CA43]	[34]
Bromfenac	DMKB79O	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Bromfenac.	Postoperative inflammation [1A00-CA43]	[27]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Diclofenac caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[28]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Diclofenac caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Diclofenac and Epoprostenol.	Pulmonary hypertension [BB01]	[79]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Diclofenac and Iloprost.	Pulmonary hypertension [BB01]	[79]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Everolimus.	Renal cell carcinoma [2C90]	[80]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Temsirolimus.	Renal cell carcinoma [2C90]	[80]
Meloxicam	DM2AR7L	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Meloxicam.	Rheumatoid arthritis [FA20]	[27]
Sulindac	DM2QHZU	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Sulindac.	Rheumatoid arthritis [FA20]	[27]
Oxaprozin	DM9UB0P	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Oxaprozin.	Rheumatoid arthritis [FA20]	[27]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Flurbiprofen.	Rheumatoid arthritis [FA20]	[27]
Sulfasalazine	DMICA9H	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Sulfasalazine.	Rheumatoid arthritis [FA20]	[61]
Dexamethasone	DMMWZET	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Dexamethasone.	Rheumatoid arthritis [FA20]	[34]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Diclofenac and Leflunomide.	Rheumatoid arthritis [FA20]	[58]
Methylprednisolone	DM4BDON	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[34]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[30]
Armodafinil	DMGB035	Minor	Increased metabolism of Diclofenac caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[75]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Pitolisant.	Somnolence [MG42]	[30]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Diclofenac and Naltrexone.	Substance abuse [6C40]	[81]
Warfarin	DMJYCVW	Moderate	Increased risk of bleeding by the combination of Diclofenac and Warfarin.	Supraventricular tachyarrhythmia [BC81]	[33]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Diclofenac and Plicamycin.	Testicular cancer [2C80]	[33]
Deferiprone	DMS2M7O	Moderate	Decreased metabolism of Diclofenac caused by Deferiprone mediated inhibition of UGT.	Thalassaemia [3A50]	[82]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Diclofenac caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[83]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Diclofenac and Caplacizumab.	Thrombocytopenia [3B64]	[33]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Diclofenac and Apixaban.	Thrombosis [DB61-GB90]	[30]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Diclofenac and Cangrelor.	Thrombosis [DB61-GB90]	[33]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Diclofenac and Brilinta.	Thrombosis [DB61-GB90]	[30]
Clopidogrel	DMOL54H	Moderate	Increased risk of bleeding by the combination of Diclofenac and Clopidogrel.	Thrombosis [DB61-GB90]	[33]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Diclofenac and Cabozantinib.	Thyroid cancer [2D10]	[84]
Sirolimus	DMGW1ID	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Sirolimus.	Transplant rejection [NE84]	[80]
Tacrolimus	DMZ7XNQ	Major	Increased risk of nephrotoxicity by the combination of Diclofenac and Tacrolimus.	Transplant rejection [NE84]	[80]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[29]
Chlorpropamide	DMPHZQE	Moderate	Increased risk of hypoglycemia by the combination of Diclofenac and Chlorpropamide.	Type 2 diabetes mellitus [5A11]	[29]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Olsalazine.	Ulcerative colitis [DD71]	[61]
Cinoxacin	DM4EWNS	Moderate	Additive CNS depression effects by the combination of Diclofenac and Cinoxacin.	Urinary tract infection [GC08]	[35]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Diclofenac and Plazomicin.	Urinary tract infection [GC08]	[36]
Nalidixic acid	DMRM0JV	Moderate	Additive CNS depression effects by the combination of Diclofenac and Nalidixic acid.	Urinary tract infection [GC08]	[35]
Triamcinolone	DM98IXF	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Diclofenac and Triamcinolone.	Vasomotor/allergic rhinitis [CA08]	[34]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Diclofenac and Betrixaban.	Venous thromboembolism [BD72]	[85]
-----------


⏷ Show the Full List of 160 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aceglutamide aluminum	E00507	10463869	Other agent
Allura red AC dye	E00338	33258	Colorant
Cetyl alcohol	E00061	2682	Coating agent; Emollient; Emulsifying agent; Stiffening agent
D&C red no. 27	E00381	83511	Colorant
Dihydroxyaluminum aminoacetate	E00527	16683036	Buffering agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrochloric acid	E00015	313	Acidulant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Aluminum trihydroxide	E00505	10176082	Alkalizing agent; Vaccine adjuvant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium phosphate	E00298	24456	Anticaking agent; Buffering agent; Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Cetostearyl alcohol	E00353	62238	Emollient; Emulsifying agent; Viscosity-controlling agent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 2000	E00649	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate	E00671	Not Available	Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 47 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Diclofenac 50 mg tablet	50 mg	Delayed Release Oral Tablet	Oral
Diclofenac 75 mg tablet	75 mg	Delayed Release Oral Tablet	Oral
Diclofenac 18 mg capsule	18 mg	Oral Capsule	Oral
Diclofenac 35 mg capsule	35 mg	Oral Capsule	Oral
Diclofenac 25 mg capsule	25 mg	Oral Capsule	Oral
Diclofenac 50 mg tablet	50 mg	Oral Tablet	Oral
Diclofenac 100 mg tablet	100 mg	24 HR Extended Release Oral Tablet	Oral
Diclofenac 25 mg tablet	25 mg	Delayed Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Diclofenac FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Davies NM, Anderson KE: Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls. Clin Pharmacokinet. 1997 Sep;33(3):184-213. doi: 10.2165/00003088-199733030-00003.
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	Todd PA, Sorkin EM: Diclofenac sodium. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1988 Mar;35(3):244-85. doi: 10.2165/00003495-198835030-00004.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
9	Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
10	Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
11	Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
12	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
13	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
14	Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
15	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
16	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
19	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
20	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
21	The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505.
22	Hydroxylation of Compactin (ML-236B) by CYP105D7 (SAV_7469) from Streptomyces avermitilis. J Microbiol Biotechnol. 2017 May 28;27(5):956-964.
23	Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
24	Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
25	15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells. Arch Biochem Biophys. 2009 Jul 15;487(2):139-45. doi: 10.1016/j.abb.2009.05.017. Epub 2009 Jun 6.
26	Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
27	Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
30	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
31	Altman R, Scazziota A, Dujovne C "Diltiazem potentiates the inhibitory effect of aspirin on platelet aggregation." Clin Pharmacol Ther 44 (1988): 320-5. [PMID: 3416553]
32	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
33	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
34	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
35	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
36	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
37	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
38	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
39	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
41	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
42	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
43	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
44	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
45	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
46	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
47	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
48	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
49	Canadian Pharmacists Association.
50	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
51	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
52	Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
53	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
54	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
55	Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
56	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
57	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
58	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
59	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
60	Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
61	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
62	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
63	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
64	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
65	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
66	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
67	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
68	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
69	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
70	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
71	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
72	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
73	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
74	Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
75	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
76	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
77	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
78	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
79	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
80	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
81	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
82	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
83	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
84	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
85	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.